Navigation Links
NIST announces 56 new awards for innovative technology research and development
Date:9/28/2007

The National Institute of Standards and Technology (NIST) today announced 56 new awards for innovative industrial research and development projects under the agencys Advanced Technology Program (ATP).

The new awards represent a broad range of technologies, including medical diagnostic techniques, alternative energy sources, manufacturing, semiconductor electronics, transportation, nanotechnology, energy conservation and automated language translation, among others. The new awards potentially represent a total of up to $138.7 million in ATP funding together with an industry cost-share of up to $104 million, if all projects are carried through to completion. ATP awards are made contingent on available funding and on evidence of satisfactory progress throughout the multi-year research schedules.

The 56 projects were chosen in a competition announced last April and represent the last set of R&D projects to be funded under the ATP, which was abolished under the America COMPETES Act (P.L. 110-69). The act allows for continued support for ongoing ATP projects, including those chosen in the FY 2007 competition. The ATP provided cost-shared support to enable or accelerate high-risk industrial research projects. Projects were selected for funding by a competitive, peer-reviewed process that evaluated the scientific and technical merit of each proposal and the potential for broad-based benefits to the nation if the technology were successfully developed.

For additional details and a list of the 56 new projects, see NIST Announces 56 New Awards For Innovative Technology R&D.


'/>"/>

Contact: Michael Baum
michael.baum@nist.gov
301-975-2763
National Institute of Standards and Technology (NIST)
Source:Eurekalert

Page: 1

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
5. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
6. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
7. GlycoFi announces the first production of antibodies with human glycosylation in yeast
8. NHGRI announces new sequencing targets
9. CHAVI announces international search for genes affecting HIV response
10. NHGRI announces latest sequencing targets
11. MUHC announces a transplant first in Quebec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... , December 5, 2016 ... "Cell Expansion Market, by Products (Consumable, Instruments, Automated ... (Regenerative Medicine and Stem Cell Research, Cancer, and ... Institutes, Cell Banks) - Global Revenue, Trends, Growth, ... Scalar Market Research, the global cell expansion market ...
(Date:12/5/2016)... 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... and Safety Monitoring Board (DSMB) for the Company,s ... (CVD) patients has completed a second planned safety ... as planned without any modifications. The DSMB reviewed ... or efficacy concerns were identified. The DSMB will ...
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/5/2016)... 5, 2016 The U.S. Biotechnology ... $108 billion of revenue and some $890 billion of ... on global biopharmaceuticals, and this figure is expected to ... lined up these four equities for assessment: Northwest Biotherapeutics ... (NASDAQ: ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
Breaking Biology Technology: